Global Proton Therapy Market 2024–2033

Reports Description

Global Proton Therapy Market was valued at USD 680.0 Million in 2022 and is expected to reach USD 2,405.6 Million by 2032, at a CAGR of 12.11% during the forecast period 2023 - 2032.

Proton Therapy is a type of radiation therapy that uses protons rather than X-rays. It painlessly delivers radiation to treat some types of cancer.

Proton therapy is effective in treating cancers that are not metastatic and tumours that are in or near critical areas such as the brain, heart and lungs. At present, the types of cancers best treated with proton therapy include Brain cancer and spinal tumours.

Proton Therapy Market Growth Factors

Increasing Incidence of Cancer

The rising prevalence of cancer worldwide is a significant driver for the global proton therapy market. According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality globally, with approximately 10 million deaths attributed to cancer in 2020 alone.

The demand for effective cancer treatment options such as proton therapy is growing, as it offers precise targeting of tumours while minimizing damage to surrounding healthy tissues. This increasing incidence of cancer is expected to drive the adoption of proton therapy systems in the coming years.

Technological Advancements

Technological advancements in proton therapy systems are driving market growth by enhancing treatment precision, reducing side effects, and improving patient outcomes. Innovations such as pencil beam scanning (PBS) and intensity-modulated proton therapy (IMPT) allow for more precise targeting of tumours, thereby minimizing damage to nearby organs and tissues.

Additionally, advancements in imaging technologies such as MRI-guided proton therapy further improve treatment accuracy. These technological advancements not only increase the efficacy of proton therapy but also expand its applicability to a wider range of cancer types and stages, driving market growth.

Proton Therapy Market Restraints

High Treatment Costs

One of the primary restraints hindering the widespread adoption of proton therapy is the high treatment costs associated with its implementation. The capital investment required to establish proton therapy centers, along with the operational expenses and maintenance costs, significantly contributes to the overall cost of treatment.

Moreover, the limited reimbursement coverage for proton therapy by healthcare payers further exacerbates the financial burden on patients and healthcare providers. As a result, the high cost of proton therapy remains a significant barrier to access for many patients, thereby restraining market growth.

Limited Availability of Centers

The limited availability of proton therapy centers in certain regions poses a challenge to market growth. Proton therapy requires specialized infrastructure and equipment, which limits its accessibility, particularly in developing countries and rural areas.

The concentration of proton therapy centers in select regions or countries leads to disparities in access to treatment, with patients in remote areas facing challenges in receiving proton therapy services. The shortage of treatment facilities and long waiting times at existing centers further exacerbate this issue, thereby restraining market growth opportunities.

Proton Therapy Market Opportunities

Growing Aging Population

The global aging population presents a significant market opportunity for proton therapy providers. According to the United Nations, the proportion of the world's population aged 60 years and older is expected to nearly double by 2050. Since cancer incidence increases with age, the growing elderly population is likely to drive the demand for cancer treatments, including proton therapy.

Moreover, older adults often have comorbidities or conditions that make them more susceptible to the side effects of traditional cancer treatments, making proton therapy an attractive alternative due to its precision and reduced toxicity.

Expansion into Emerging Markets

Expanding into emerging markets presents a lucrative opportunity for proton therapy market players to tap into new sources of revenue. Emerging economies are witnessing rapid urbanization, improving healthcare infrastructure, and increasing healthcare expenditure, which are driving the demand for advanced cancer treatment modalities.

By establishing partnerships with local healthcare providers and investing in infrastructure development, proton therapy companies can penetrate these markets and cater to the unmet need for advanced cancer care. Additionally, government initiatives aimed at improving cancer care access and affordability in emerging markets further support market expansion opportunities for proton therapy providers.

Proton Therapy Market Segmentation Analysis

The Global Proton Therapy market is segmented by setup type, application, end user, technology and delivery system.

Based on the setup type, proton therapy is segmented into Single-Room Systems, Multi-Room Systems. Among these all-segments Multi-Room Systems held the highest market share in 2022. Multi-room systems are typically more versatile and can accommodate a higher volume of patients compared to single-room systems.

Single-room systems are often favoured for their cost-effectiveness and flexibility in terms of space requirements, making them increasingly popular, especially in smaller healthcare facilities or regions where space is limited.

Based on the application, proton therapy is segmented into Paediatric Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Brain Cancer and Others (e.g., gastrointestinal cancers, ocular tumours). Among all these segments Prostate Cancer held the highest market share in 2022.

Prostate cancer is one of the most common types of cancer treated with proton therapy due to the precise targeting capabilities of the technology and its ability to minimize damage to surrounding tissues. Lung cancer treatment with proton therapy is gaining traction due to its ability to target tumours in delicate areas near critical structures such as the heart and lungs, leading to increased adoption and growth in this subsegment.

Based on the end user, proton therapy is segmented into Hospitals, Proton Therapy Centers, and Ambulatory Surgical Centers. Among all these segments Hospitals held the highest market share in 2022. Hospitals have been the traditional setting for proton therapy treatment due to their comprehensive healthcare facilities and infrastructure.

Proton therapy centers dedicated solely to providing proton therapy treatments are emerging as a specialized option, attracting patients seeking focused care and expertise in this advanced treatment modality.

Based on the technology, proton therapy is segmented into Cyclotron-Based Systems and Synchrotron-Based Systems. Among all these segments Cyclotron-Based Systems held the highest market share in 2022.

Cyclotron-based systems have been widely used in proton therapy due to their established technology and reliability. Synchrotron-based systems offer advantages such as higher beam intensity and energy modulation, driving their adoption in proton therapy and contributing to their faster growth rate.

Based on the delivery method, proton therapy is segmented into Fixed Beam and Scanning Beam. Among all these segments Fixed Beam held the highest market share in 2022. The fixed beam delivery method is more commonly used, offering stable and predictable treatment delivery.

The scanning beam delivery method allows for more precise targeting of tumours with complex shapes or those located near critical structures, making it increasingly preferred and driving its growth in the market

Report Scope

Proton Therapy Market: Regional Analysis

The global proton therapy market is experiencing significant growth, with Asia Pacific emerging as the fastest-growing region, while North America maintains its leadership position. Several factors contribute to the rapid expansion of proton therapy in Asia Pacific. Firstly, the region is witnessing a surge in cancer cases, prompting a demand for advanced treatment options like proton therapy due to its precise targeting and minimal damage to healthy tissues.

Additionally, countries in the Asia Pacific, including China, Japan, South Korea, and India, are investing heavily in upgrading their healthcare infrastructure, making proton therapy more accessible to patients. Technological advancements and supportive government initiatives further drive growth, with Asia Pacific actively participating in research and development to innovate treatment efficacy and implementing policies to encourage adoption.

Despite Asia Pacific's rapid growth, North America remains the leading region in the global proton therapy market. This is attributed to its well-established healthcare infrastructure, high concentration of proton therapy centers, and early adoption of the treatment. Robust reimbursement policies, coupled with high patient awareness and education, ensure accessibility to proton therapy in North America.

Moreover, strategic partnerships and investments in research and development strengthen the region's position as a leader in the field. Overall, both Asia Pacific and North America play crucial roles in driving the growth and advancement of proton therapy worldwide, catering to the increasing demand for effective cancer treatment options.

To learn more about this report - request a sample report PDF

List of the prominent players in the Proton Therapy Market:

• Advanced Oncotherapy plc
• Hitachi
• IBA worldwide
• Ion Beam Applications SA
• Mevion Medical Systems
• Mitsubishi Electric Corporation
• Optivus Proton Therapy
• ProTom International
• Provision Healthcare
• Sumitomo Heavy Industries Ltd.
• Varian
• Others

These key players are adopting various organic and inorganic growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.

Proton Therapy Market: Recent Developments

• In January 2024, Varian Medical Systems Announced a Collaboration with Elekta AB. Varian and Elekta signed a collaboration agreement to develop and commercialize proton therapy treatment planning software. This partnership brings together expertise from both companies to create a more comprehensive and user-friendly solution for clinicians. This collaboration could potentially accelerate the adoption of proton therapy by making it easier for clinicians to use and integrate into their workflows.

• In December 2023, Optivus Proton Therapy Received FDA Clearance for Pencil Beam Scanning Technology. Optivus received FDA clearance for its pencil beam scanning (PBS) technology, a more precise and efficient form of proton therapy delivery. This clearance allows Optivus to market and sell its PBS-equipped proton therapy systems in the US. This FDA clearance expands Optivus' market reach and positions it as a major player in the advanced proton therapy technology space.

• In November 2023, IBA Launched the ProteusONE+ Pencil Beam Scanning System. IBA launched its ProteusONE+ system, a compact and versatile PBS proton therapy system designed for smaller treatment centers and hospitals. This system offers a more affordable and accessible option for providing proton therapy. The ProteusONE+ could help expand access to proton therapy in regions with limited resources, potentially driving market growth.

The Proton Therapy Market is segmented as follows:

By Setup Type

• Single-Room Systems
• Multi-Room Systems

By Application

• Pediatric Cancer
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Head and Neck Cancer
• Brain Cancer
• Others (e.g., gastrointestinal cancers, ocular tumours)

By End-User

• Hospitals
• Proton Therapy Centers
• Ambulatory Surgical Centers

By Technology

• Cyclotron-Based Systems
• Synchrotron-Based Systems

By Delivery Method

• Fixed Beam
• Scanning Beam

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America